List of Excipients in Branded Drug PREGABALIN EXTENDED RELEASE

Generic Drugs Containing PREGABALIN EXTENDED RELEASE

Company	Ingredient	NDC	Excipient
Alvogen Inc	pregabalin	47781-379	AMMONIA
Alvogen Inc	pregabalin	47781-379	BUTYL ALCOHOL
Alvogen Inc	pregabalin	47781-379	CROSPOVIDONE
Alvogen Inc	pregabalin	47781-379	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
Alvogen Inc	pregabalin	47781-379	FERROSOFERRIC OXIDE
Alvogen Inc	pregabalin	47781-379	HYDROXYPROPYL CELLULOSE
Alvogen Inc	pregabalin	47781-379	HYPROMELLOSE 2208

What are the Most Frequently-Used Excipients in PREGABALIN EXTENDED RELEASE?

# Of NDCs	Excipient
1	AMMONIA
1	BUTYL ALCOHOL
1	CARBOMER HOMOPOLYMER TYPE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
1	FERRIC OXIDE RED

Pregabalin Extended-Release Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Pregabalin extended-release is an established oral modified-release platform with limited branded competition, expired basic-molecule protection, and potential value in generic, 505(b)(2), reformulation, and contract-development programs. The main technical challenge is controlling release from a highly water-soluble drug while preserving dose proportionality, tablet integrity, food-effect performance, and bioequivalence to the reference product, Lyrica CR.

The commercial opportunity is strongest for low-cost generic development, differentiated once-daily products, and regional licensing. The opportunity is weaker for a premium branded launch because Pfizer discontinued U.S. commercialization of Lyrica CR after limited market uptake.

What is pregabalin extended release?

Pregabalin extended release is a once-daily oral formulation of pregabalin, an alpha-2-delta calcium-channel ligand used for neuropathic pain and related indications.

Pfizer’s Lyrica CR was approved by the FDA in 2017 for:

• Diabetic peripheral neuropathy.
• Postherpetic neuralgia.

Lyrica CR was not approved for fibromyalgia, an indication associated with immediate-release Lyrica. The approved strengths were 82.5 mg, 165 mg, and 330 mg tablets. The product was administered once daily after an evening meal and was required to be swallowed whole. It was not substitutable on a milligram-for-milligram basis with immediate-release pregabalin because the products have different release profiles, dosing schedules, and food instructions (U.S. Food and Drug Administration [FDA], 2017).

Reference product profile

Attribute	Lyrica CR
Active ingredient	Pregabalin
Dosage form	Extended-release tablet
Strengths	82.5 mg, 165 mg, 330 mg
Administration	Once daily after an evening meal
Approved indications	Diabetic peripheral neuropathy; postherpetic neuralgia
Reference sponsor	Pfizer
FDA approval	2017
Immediate-release substitution	Not directly interchangeable
Product status	U.S. commercial availability discontinued by Pfizer
Primary formulation challenge	Sustained release of a highly soluble, rapidly absorbed drug

What excipients are used in pregabalin extended-release tablets?

The Lyrica CR formulation uses a conventional matrix-tablet excipient system rather than an osmotic pump or multiparticulate capsule. The FDA label identifies excipients including hypromellose, microcrystalline cellulose, lactose monohydrate, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, and talc, with colorants varying by strength (FDA, 2017).

The excipient architecture has four functional groups:

Functional role	Likely excipient classes	Development purpose
Release-controlling matrix	Hypromellose and related hydrophilic polymers	Hydration, gel formation, diffusion and erosion control
Tablet structure	Microcrystalline cellulose, lactose	Compression, dilution, hardness, content uniformity
Granulation and binding	Povidone	Granule strength and processability
Disintegration and processing	Crospovidone, colloidal silicon dioxide	Controlled tablet breakup, flow improvement
Lubrication and surface treatment	Magnesium stearate, talc, sodium lauryl sulfate	Ejection, lubrication, wetting, coating performance
Film coating	Hypromellose-based coating systems, pigments	Appearance, identification, handling

The formulation strategy is commercially relevant because the drug has high aqueous solubility and does not require a solubility-enhancing formulation. The excipient system must slow drug liberation without causing dose dumping, excessive tablet size, or unacceptable variability after food intake.

Which excipient strategy is best for pregabalin extended release?

A hydrophilic polymer matrix is the most practical starting point for a generic or 505(b)(2) product. Hypromellose is commercially available, scalable, widely accepted by regulators, and compatible with direct compression or wet granulation.

Hydrophilic matrix strategy

Hypromellose grades with different viscosity and substitution profiles can be combined to tune release. Higher-viscosity grades generally increase gel strength and slow erosion. The formulation must be optimized against:

• Polymer concentration.
• Polymer viscosity grade.
• Drug-to-polymer ratio.
• Tablet hardness and porosity.
• Granule density.
• Lubrication time.
• Dissolution medium and agitation rate.
• Fed and fasted gastrointestinal conditions.

A single-polymer system is simpler to manufacture but may have limited flexibility across the 82.5 mg, 165 mg, and 330 mg strengths. A polymer blend can improve release matching but increases formulation complexity and scale-up risk.

Hydrophobic matrix strategy

Hydrophobic excipients such as glyceryl behenate, hydrogenated vegetable oils, or ethylcellulose can reduce water ingress and provide longer release. They may be useful where a hydrophilic matrix releases pregabalin too rapidly.

The tradeoffs include:

• Greater sensitivity to granulation and lubrication conditions.
• Potential food-effect changes.
• More difficult dissolution matching.
• Higher risk of incomplete release.
• Increased formulation differentiation from the reference product.

A hydrophobic matrix is more appropriate for a differentiated 505(b)(2) product than for a conventional ANDA intended to match Lyrica CR closely.

Coated multiparticulates

Pregabalin can be layered onto pellets or incorporated into matrix multiparticulates, followed by a polymeric rate-controlling coat. This approach can reduce unit-to-unit variability and permit capsule or sachet delivery.

Commercial advantages include:

• Flexible dose titration.
• Potential sprinkle or suspension administration.
• Better control over dose dumping.
• Reduced dependence on one large monolithic tablet.

Commercial disadvantages include:

• More complex equipment.
• Higher manufacturing cost.
• More demanding content-uniformity testing.
• Greater risk of intellectual-property overlap with controlled-release coating patents.
• More difficult bioequivalence development if the reference is a matrix tablet.

Osmotic delivery systems

An osmotic tablet could provide a robust release profile for a highly soluble compound. The technology may reduce sensitivity to gastrointestinal agitation, but it requires specialized manufacturing, laser drilling or membrane control, and tighter process specifications.

For a generic product, an osmotic platform is likely economically unattractive unless it produces a clear clinical or regulatory advantage. It may be more defensible for a new indication, a lower-dose regimen, or a product requiring reduced food dependence.

What formulation patents protect pregabalin extended release?

The basic pregabalin compound patent no longer provides the principal barrier to entry. The relevant protection has shifted to controlled-release formulations, dosage regimens, manufacturing processes, and potentially specific excipient or dissolution profiles.

Key patent categories include:

1. Controlled-release pregabalin matrix tablets.
2. Once-daily dosing for neuropathic pain.
3. Release profiles designed for evening administration.
4. Food-effect management.
5. Coated multiparticulate or osmotic systems.
6. Processes for granulation, compression, and coating.
7. Specific excipient ratios or dissolution windows.

The FDA Orange Book, issued patents, patent-term adjustments, terminal disclaimers, and litigation records must be reviewed together. An Orange Book listing can affect ANDA certification and litigation timing, while unlisted formulation patents can still create infringement exposure after approval.

The original Lyrica compound protection expired in the United States in 2018. Lyrica CR had separate regulatory and formulation protection. The commercial importance of those rights declined after Pfizer ended U.S. promotion and sales, but they remain relevant to generic launch planning and freedom-to-operate analysis.

When did pregabalin extended-release exclusivity expire?

Lyrica CR did not receive new chemical entity exclusivity because pregabalin had already been approved in the United States. The product received regulatory protection associated with new clinical investigations and the extended-release formulation.

The principal timeline is:

Event	Approximate date
Pregabalin immediate-release approval	2004
Original compound patent expiry	2018
Lyrica CR approval	June 2017
Three-year clinical investigation exclusivity period	Approximately through June 2020
Commercial discontinuation by Pfizer	After limited market uptake
Current strategic focus	Generic, reformulation, licensing, and regional supply

Exact patent expiration dates depend on the patent family, patent-term adjustment, patent-term extension, and any terminal disclaimer. A launch assessment should use the current Orange Book and Patent and Exclusivity data rather than rely on the compound expiry date alone.

What FDA regulatory pathways are available?

ANDA pathway

An ANDA is the most direct route for a product designed to match Lyrica CR. The applicant must establish pharmaceutical equivalence and demonstrate bioequivalence using FDA-specified studies, including extended-release pharmacokinetic comparisons and dissolution testing.

The principal ANDA risks are:

• Failure to match the reference product under fed conditions.
• Food-related dose dumping.
• Inability to reproduce the reference release profile.
• Differences in inactive ingredients that affect tolerability or absorption.
• Paragraph IV litigation against listed formulation patents.

505(b)(2) pathway

A 505(b)(2) application can support a product that differs from Lyrica CR in dosage form, administration conditions, strength, or delivery technology while relying partly on FDA findings for pregabalin.

Potential 505(b)(2) concepts include:

• Pregabalin ER without a required evening meal.
• A sprinkle capsule or oral granule.
• A lower-dose once-daily product.
• A tablet designed for reduced peak concentrations.
• A combination product.
• A product for patients with swallowing difficulty.

A 505(b)(2) strategy has greater formulation freedom than an ANDA but can face clinical bridging requirements, patent certifications, and narrower reimbursement positioning.

Product-line extension

A manufacturer with immediate-release pregabalin can use an ER product to retain prescriber and pharmacy relationships after immediate-release patent expiry. The commercial case depends on whether the product provides a meaningful adherence, tolerability, or dosing benefit.

What generic entry risks exist for pregabalin extended release?

Generic entry risk is structurally high because pregabalin is a small molecule with extensive clinical history and no biosimilar barrier. The principal barriers are formulation and regulatory execution rather than active-ingredient synthesis.

Paragraph IV challenges

An ANDA applicant may certify that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger patent litigation and a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and court decisions.

The most relevant claims are likely to concern:

• Polymer-controlled release.
• Specific dissolution ranges.
• Once-daily dosing.
• Fed-state administration.
• Strength-specific compositions.
• Manufacturing parameters.

A non-infringing excipient system can reduce litigation exposure but may increase bioequivalence risk. A close formulation match can improve regulatory probability while increasing patent overlap. The optimal design depends on the strength of the asserted claims and the expected value of an early launch.

Generic launch scenarios

Scenario	Regulatory route	Commercial outcome
Close matrix-tablet match	ANDA	Lowest clinical burden; higher patent overlap
Distinct matrix composition	ANDA with non-infringement position	Moderate formulation risk; potentially better patent position
Multiparticulate or sprinkle product	505(b)(2)	Differentiated product; higher development cost
Osmotic tablet	505(b)(2) or complex generic route	Stronger technical differentiation; weak cost position
Immediate-release substitution	Not equivalent to Lyrica CR	Separate product strategy, not an ER replacement

How strong is the pregabalin extended-release patent estate?

The patent estate is moderate rather than dominant.

Its strengths are:

• A protected extended-release dosage form rather than an unprotected immediate-release product.
• Potentially narrow formulation and release-profile claims.
• Regulatory leverage through Orange Book listings.
• Ability to delay ANDA approval through litigation.

Its weaknesses are:

• Expired basic compound protection.
• A highly genericized active ingredient.
• Availability of alternative release technologies.
• Limited commercial traction for the branded ER product.
• Potential difficulty proving broad patent claims around conventional matrix excipients.

A generic applicant should prioritize claim-charting of polymer type, concentration, dissolution method, strength, and fed-state performance. A formulation that uses common excipients but avoids claimed ratios may offer the best balance between regulatory similarity and freedom to operate.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target pregabalin ER through formulation platforms rather than commodity sales.

High-value opportunities

• High-viscosity hypromellose grades for matrix control.
• Direct-compression excipient systems that reduce process variability.
• Co-processed fillers and binders for high-dose tablets.
• Hydrophobic release modifiers for food-effect control.
• Film-coating systems with strength-specific color matching.
• Ready-to-use granulation systems for contract manufacturers.
• Dissolution-screening and formulation-development services.
• Excipient combinations supported by regulatory precedents.

The most attractive supplier position is a validated platform that improves release consistency across all three strengths. Technical support should focus on scale-up, dissolution robustness, compression force, and stability rather than simply providing a lower-cost excipient.

How does pregabalin extended release compare with immediate-release pregabalin?

Factor	Immediate-release pregabalin	Extended-release pregabalin
Dosing	Usually multiple daily doses	Once daily
Formulation complexity	Low	Moderate to high
Food instruction	Less restrictive	Evening meal required for Lyrica CR
Generic competition	Extensive	More limited
Patent risk	Low after compound expiry	Formulation and method-of-use risk
Excipient value	Primarily manufacturing efficiency	Release control and bioequivalence
Commercial differentiation	Limited	Adherence and dosing convenience
Development route	ANDA	ANDA or 505(b)(2)

What is the revenue and competitive outlook?

Pregabalin has a large established market because of neuropathic pain, epilepsy, and fibromyalgia use. Most volume has shifted toward immediate-release generics. The extended-release segment is smaller and has not demonstrated the same commercial durability as the original Lyrica franchise.

The strongest commercial opportunities are:

1. Low-cost generic Lyrica CR supply in markets with limited competition.
2. Regional licensing where Pfizer’s product is unavailable.
3. A differentiated once-daily product with simpler food requirements.
4. A sprinkle, granule, or swallow-friendly formulation.
5. Contract manufacturing for branded or private-label products.
6. Combination or adherence-oriented products supported by a 505(b)(2) strategy.

Biosimilar risk is not relevant because pregabalin is a synthetic small molecule, not a biologic. Competitive risk comes from immediate-release pregabalin generics, alternative neuropathic-pain medicines, duloxetine, gabapentin, and branded or generic combination therapies.

What geographic markets offer opportunity?

The United States offers the clearest legal framework but also the highest requirement for Orange Book, Paragraph IV, and bioequivalence analysis. Europe and other regulated markets may offer opportunities through decentralized or national generic procedures, depending on reference-product status and local patent rights.

Priority markets should be screened for:

• Current Lyrica CR availability.
• Local generic registration requirements.
• Patent-family status.
• Prescription volume for once-daily pregabalin.
• Reimbursement for modified-release products.
• Ability to use a local reference product.
• Manufacturing and import requirements.

A global excipient or finished-dose strategy should not assume that U.S. bioequivalence data automatically supports every jurisdiction. Release specifications, food instructions, labeling, and reference-product requirements can differ.

Key Takeaways

• Pregabalin ER is a formulation-driven opportunity, not a molecule-patent opportunity.
• Hydrophilic hypromellose matrix tablets are the most practical development platform.
• The principal technical risks are food effect, dose dumping, dissolution matching, and strength scalability.
• Lyrica CR was approved in 2017 for diabetic peripheral neuropathy and postherpetic neuralgia.
• The original pregabalin compound patent expired in 2018; remaining risk centers on formulation, method-of-use, and manufacturing patents.
• ANDA development offers the lowest clinical burden but may create greater patent overlap.
• A 505(b)(2) strategy supports differentiated dosage forms, food instructions, and administration routes.
• Biosimilar competition is irrelevant; immediate-release generics are the main competitive substitute.
• Excipient suppliers can create value through validated matrix systems, co-processed materials, and dissolution-control platforms.
• The strongest commercial candidates are low-cost generics, regional licenses, and differentiated once-daily or swallow-friendly products.

FAQs

Can pregabalin extended-release tablets be crushed?

Lyrica CR tablets are intended to be swallowed whole. Crushing, splitting, or chewing can alter release and increase the risk of inappropriate drug release.

Is pregabalin extended release interchangeable with generic pregabalin?

No. Immediate-release pregabalin and extended-release pregabalin have different dosing schedules, food requirements, release profiles, and regulatory equivalence standards.

Which polymer is most commonly used in pregabalin ER development?

Hypromellose is the leading starting polymer because it forms a controllable hydrophilic gel matrix and has broad regulatory acceptance.

Can a pregabalin ER product avoid administration after an evening meal?

A differentiated formulation may be designed for reduced food dependence, but that change would require appropriate pharmacokinetic and regulatory support. It would not automatically qualify as an ANDA-equivalent product.

Is pregabalin extended release a good candidate for abuse-deterrent formulation?

The opportunity is limited compared with opioids. Abuse-deterrent technology could add cost without a clear regulatory or reimbursement benefit unless supported by a defined misuse-risk strategy.

References

1. U.S. Food and Drug Administration. (2017). Lyrica CR (pregabalin) extended-release tablets prescribing information. Pfizer Inc.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Approved drug products and patent and exclusivity information. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2012). Guidance for industry: Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2022). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. U.S. Department of Health and Human Services.

6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.